Quantcast
Last updated on April 16, 2014 at 13:48 EDT

Latest gabapentin Stories

2008-11-03 15:00:21

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced results of a study in which Azilect(R) (rasagiline tablets) demonstrated selective MAO-B inhibition at the approved dose of 1mg. Non selective MAO inhibitors may have some contra indications with certain foods and drugs. These limitations are not associated with selective MAO inhibitors and therefore they can be broadly prescribed. Based on these positive results, Teva will work with the U.S. Food and Drug Administration...

2008-10-27 06:00:23

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it has entered into a settlement agreement with an institution that acted as a broker in placing investments in Teva's portfolio of auction rate securities. In consideration for a full release of the institution, Teva has received a cash payment of $100 million. Due to confidentially restrictions, additional information will not be disclosed. Teva will record this payment as one time finance income and will exclude...

2008-10-20 06:00:22

Depomed, Inc. (NASDAQ:DEPO) announced today the enrollment and dosing of the first patient in Breeze 2, the second of two pivotal Phase 3 clinical trials in Depomed's registration program for DM-5689 (formerly referred to as Gabapentin GR(R)) for the treatment of menopausal hot flashes. Breeze 1, the first Phase 3 clinical trial, was initiated in September. "I look forward to the results of Depomed's Phase 3 trials for DM-5689 in menopausal hot flashes after having seen Depomed's...

2008-10-16 06:00:31

Depomed, Inc. (NASDAQ:DEPO) today announced that it will release third quarter financial results for 2008 after the market closes on Thursday, October 30, 2008. The company will webcast a conference call beginning at 5:00 p.m. ET, 2:00 p.m. PT to discuss its results and to provide an update and future outlook on company events. Interested parties can access the live and archived broadcast of the call at www.depomedinc.com. About Depomed Depomed, Inc. is a specialty...

2008-10-16 03:00:19

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has entered into a definitive agreement to sell its Israeli based veterinary business unit to Phibro Animal Health Corporation, for total consideration of approximately $47 million. The transaction is subject to certain conditions, including Israeli antitrust approvals and other closing conditions, and is expected to close in the first quarter of 2009. Teva's veterinary business unit in Israel develops,...

2008-09-25 17:46:23

Depomed, Inc. (Nasdaq:DEPO) today announced the presentation of data from its Phase 2 study of DM-5689 (formerly referred to as Gabapentin GR(R)) for the treatment of women with moderate-to-severe menopausal hot flashes. As previously disclosed, DM-5689 significantly reduced the frequency and severity of hot flashes from baseline to the end of treatment compared to placebo in the 124 patient study. The data were presented today at the North American Menopause Society (NAMS) Annual...

2008-09-23 18:00:13

Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved ProAir(R) HFA (albuterol sulfate) Inhalation Aerosol for use in patients as young as 4 years of age. Previously, ProAir HFA had been indicated for use in patients aged 12 and older. In clinical studies, ProAir HFA, the market leading albuterol sulfate inhaler,(1) exhibited significant bronchodilator efficacy in pediatric asthmatics aged 4 to 11 years. ProAir HFA provides...

2008-09-22 15:00:53

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today the introduction of Nicardipine Hydrochloride Injection, 2.5 mg/mL, which is AP-rated to EKR Therapeutics' hypertension treatment Cardene(R) I.V. Teva's product is the first alternative to the brand product, which had annual sales of approximately $181 million in the United States for the twelve months ended June 30, 2008, according to IMS sales data. Teva is manufacturing and distributing the product, under license, as...

2008-09-18 15:00:38

Depomed, Inc. (NASDAQ: DEPO) today announced that president and chief executive officer, Carl A. Pelzel, will present on Tuesday, September 23, 2008 at 8:30 a.m. ET during the UBS Global Life Sciences Conference to be held in New York City. Interested parties can access a live, or archived, webcast of the presentation on the company's website at www.depomedinc.com. About Depomed Depomed, Inc. is a specialty pharmaceutical company with two approved products on the market and...

2008-09-18 15:00:38

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced new data from the longest prospective study of treatment to relapsing-remitting multiple sclerosis (RRMS), which proves robust efficacy and safety of COPAXONE(R) (glatiramer acetate injection). Findings demonstrated that more than 80 percent of patients were able to walk unassisted following 15 years of treatment and average disease duration of 22 years. The majority of the 100 patients in the study experienced either stable...